Association of thrombocytopenia with splenomegaly in malaria patients in East Kalimantan: A cross-sectional, retrospective study [version 1; peer review: 1 approved with reservations]

Loly R.D. Siagian¹, Vera M. Lumbantoruan², Nurul Hasanah³, Fransiska A. Sihotang⁴, Carta Gunawan⁵

¹Department of Clinical Pathology, Faculty of Medicine, Mulawarman University and Abdul Wahab Syahranie Hospital, East Kalimantan, Indonesia
²Department of Dermato Venereology, Faculty of Medicine Mulawarman, University and Abdul Wahab Syahranie Hospital, East Kalimantan, Indonesia
³Department of Histology, Faculty of Medicine, Mulawarman University, East Kalimantan, Indonesia
⁴Department of Physiology, Faculty of Medicine, Mulawarman University, East Kalimantan, Indonesia
⁵Department of Internal Medicine, Faculty of Medicine, Mulawarman University and Abdul Wahab Syahranie Hospital, East Kalimantan, Indonesia

Abstract

Background: Malaria still presents as a major health problem in Indonesia and specifically in East Kalimantan. One common finding in malaria is thrombocytopenia, the mechanism of which is still unclear. Several studies have suggested some mechanisms, one of which is splenomegaly. This study aimed to discover the association between thrombocytopenia and splenomegaly of malaria patients in East Kalimantan.

Methods: This study was a descriptive retrospective study with clinical and laboratory data obtained from the medical records of malaria patients in four major public hospitals from January 2015 to July 2018. The association between thrombocytopenia with splenomegaly was analysed using Chi-Square test.

Results: A total of 215 patients were included; 189 male (87.9%) and 26 female (12.1%). The most common aetiology were Plasmodium vivax (43.2%), P. falciparum (42.8%), and mixed infection (P. falciparum and P. vivax) (4.6%). The distribution of thrombocyte count were normal in 28 patients (13%) and decreased in 187 patients (87%). Among patients with thrombocytopenia, the percentage of mild, moderate and severe thrombocytopenia was 18.2%, 43.8% and 33%, respectively. Splenomegaly was found in only 11 patients (5.1%). We found no association between thrombocytopenia with splenomegaly (p=0.61).

Conclusions: We conclude that thrombocytopenia is not associated with splenomegaly in these malaria patients.

Keywords

thrombocytopenia, splenomegaly, malaria, East Kalimantan
Introduction
Malaria is still a serious health problem in Indonesia; the 2007 and 2013 Basic Health Surveys of the Health Ministry show that the prevalence of malaria in Indonesia increased from 2.9% to 6.0%.

Data from the East Kalimantan Provincial Health Office showed that there were 7,045 cases of malaria in 2010. This number fluctuated in the following years, with 3,021 cases in 2011, 9,966 cases in 2012 and 2,603 cases in 2013. In terms of Annual Parasitic Incidence (API), in 2014 East Kalimantan was still above the national average with an API of 2.04 per 1000 population, leading to it being categorized as a low cumulative incidence area.

One common finding in malaria is decreased platelet count or so-called thrombocytopenia. This laboratory finding is often confused with other infectious diseases, especially dengue infection in which thrombocytopenia is a major diagnostic parameter. There are many studies that demonstrate thrombocytopenia in malaria patients, and this is found in both infection with Plasmodium falciparum and Plasmodium vivax. The results from our previous study demonstrated that from 1041 malaria patients in East Kalimantan, 85% presented with thrombocytopenia of varying degrees. Therefore, thrombocytopenia has been suggested as one important diagnostic parameter in malaria. The mechanism of thrombocytopenia in malaria is still unclear. Several theories, such as mechanical trapping of thrombocytes inside the spleen and immune response that attacks thrombocytes, has been proposed. A study by Coelho et al. found that platelet phagocytosis may contribute to thrombocytopenia in vivax malaria.

Splenomegaly is also one common clinical finding in malaria patients. The spleen is part of the reticuloendothelial system, which becomes active in order to get rid of plasmodium-infected erythrocytes. Splenomegaly can also contribute to increased destruction of thrombocytes due to mechanical trapping. Therefore, the aim of the present study was to determine the association of thrombocytopenia with splenomegaly in malaria patients in East Kalimantan.

Methods
Study design and participants
This study was a cross-sectional retrospective study. This study was approved by the Ethical Committee for Health Research at Abdul Wahab Sjahranie Hospital Samarinda, East Kalimantan (approval number 124/KEPK-AWS/V/2018). This ethical approval also covers the research conducted in all hospitals included in our study. Patient consent for the use of their data records was waived by the ethical committee due to the retrospective nature of the study.

Data collection
Data were collected between June and August 2018 from the medical records of patients with malaria during the period of January 2015 to July 2018. Clinical and laboratory data of both outpatients and inpatients diagnosed with malaria from four major hospitals in East Kalimantan was collected. The hospitals were: Abdul Wahab Sjahranie Hospital in Samarinda, Aji Putri Botung Hospital in Penajam Paser Utara, Abdul Rivai Hospital in Tanjung Redeb, and Panglima Sebaya Hospital in Tanah Grogot.

All patients with malaria, both paediatric and adult patients, were included in the study. Patients were excluded from the study if the necessary data were incomplete or patients discharged themselves during treatment.

In order to collect data, first, the hospital’s database was searched for patients diagnosed with malaria. Second, after identifying these patients, the relevant medical records were retrieved which contained age, gender, type of Plasmodium, thrombocyte count, presence of splenomegaly.

Data analysis
For descriptive data, we described patients’ characteristics that include age, sex, type of Plasmodium, and thrombocyte count on the first day admission. The association between thrombocytopenia and splenomegaly was analyzed by Chi-square test using SPSS 23.0 software. Results were considered statistically significant if p<0.05.

Results
Our study identified a total of 215 malaria patients from January 2015 to July-2018 in five hospitals in East Kalimantan. There were 189 male patients (87.9%) and 26 female patients (12.1%). From 215 malaria patients (Table 1).

The association of thrombocytopenia with splenomegaly in malaria patients shown in Table 2. There were 11 patients with splenomegaly and 204 patients without splenomegaly. There was no association between the presence of splenomegaly and thrombocytopenia in these malaria patients (p=0.661).

Discussion
We found that the incidence of malaria was higher in males than females in this group of patients, and the parasite infecting the majority of patients was Plasmodium vivax (42.0%). This study found that thrombocytopenia affected the majority of malaria patients; thrombocytopenia occurred in 87% of patients, with moderate thrombocytopenia (43.8%) as the majority. This result is in concordance with another study by Arif et al., in India, that found that 79% of patients had moderate thrombocytopenia, while Ansari et al. found 69.18%. In the present study, the degree of thrombocytopenia classified to mild, moderate and severe was 18.2%, 43.8%, 33.0%, respectively. If we compare to study of Arif et al. that found 33.96%, 51.15% and 14.89%, respectively, we find that
the moderate thrombocytopenia was the highest percentage in both studies.

A study by Hanson et al. in Vietnam found that thrombocytopenia was a marker of disease severity in adults with *Plasmodium falciparum* infection, but has limited utility in prophylaxis, triage and management. On the other hand, Rao et al. in India found that severe thrombocytopenia showed positive correlation with complicated malaria and become a good predictor for poor prognosis. Indeed, splenomegaly is a hallmark of malaria, but the result of this study found that only 11 patients (5.1%) showed splenomegaly. In India, Gupta et al. found that only 20% malaria patients had splenomegaly, but there are no information about thromocyte count in those malaria patients with splenomegaly.

In our study, we describe the thromocyte count in malaria patients with splenomegaly. We found that there was no association between thrombocytopenia with splenomegaly (p=0.611). Therefore, we propose that thrombocytopenia is not caused by the mechanical trapping of thromocytes in the spleen. This result suggests another mechanism of thrombocytopenia that involves immune process, as proposed by Coelho et al. in 2013. Until now, the definitive mechanism of thrombocytopenia in malaria was unclear; however, some factors that contribute to thrombocytopenia have been reported, such as decreased thrombopoiesis, peripheral destruction induced by *P. falciparum* and disseminated intravascular coagulation.

This study has its limitations. Different types of automatic haematology analysers were used in the hospitals and this might contribute to variations in thromocyte count. Therefore, we suggest the use of a single haematology analyser across hospitals to improve accuracy. In addition, we did not exclude other causes of thrombocytopenia that could coexist with malaria infection, such as viral infection and autoimmune diseases, which would be require to further validate our findings. Finally, the examination of splenomegaly was conducted by different physicians, which might contribute to subjective factors in determining splenomegaly, such as physician’s expertise and thoroughness, especially in cases with minor or subclinical splenomegaly.

Overall, we conclude that thrombocytopenia is not associated with splenomegaly in this set of malaria patients.

**Table 2.** Association of thrombocytopenia with splenomegaly in malaria patient.

<table>
<thead>
<tr>
<th>Thrombocyte count</th>
<th>Splenomegaly</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Chi-Square</td>
<td></td>
<td>test p = 0.611</td>
</tr>
<tr>
<td>Normal</td>
<td></td>
<td>1</td>
<td>27</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td></td>
<td>2</td>
<td>32</td>
</tr>
<tr>
<td>Mild</td>
<td></td>
<td>6</td>
<td>76</td>
</tr>
<tr>
<td>Moderate</td>
<td></td>
<td>2</td>
<td>69</td>
</tr>
<tr>
<td>Severe (≤ 50,000)</td>
<td></td>
<td>215</td>
<td></td>
</tr>
</tbody>
</table>

The moderate thrombocytopenia was the highest percentage in both studies.

A study by Hanson et al. in Vietnam found that thrombocytopenia was a marker of disease severity in adults with *Plasmodium falciparum* infection, but has limited utility in prognostication, triage and management. On the other hand, Rao et al. in India found that severe thrombocytopenia showed positive correlation with complicated malaria and become a good predictor for poor prognosis.

Indeed, splenomegaly is a hallmark of malaria, but the result of this study found that only 11 patients (5.1%) showed splenomegaly. In India, Gupta et al. found that only 20% malaria patients had splenomegaly, but there are no information about thromocyte count in those malaria patients with splenomegaly.

In our study, we describe the thromocyte count in malaria patients with splenomegaly. We found that there was no association between thrombocytopenia with splenomegaly (p=0.611). Therefore, we propose that thrombocytopenia is not caused by the mechanical trapping of thromocytes in the spleen. This result suggests another mechanism of thrombocytopenia that involves immune process, as proposed by Coelho et al. in 2013. Until now, the definitive mechanism of thrombocytopenia in malaria was unclear; however, some factors that contribute to thrombocytopenia have been reported, such as decreased thrombopoiesis, peripheral destruction induced by *P. falciparum* and disseminated intravascular coagulation.

This study has its limitations. Different types of automatic haematology analysers were used in the hospitals and this might contribute to variations in thromocyte count. Therefore, we suggest the use of a single haematology analyser across hospitals to improve accuracy. In addition, we did not exclude other causes of thrombocytopenia that could coexist with malaria infection, such as viral infection and autoimmune diseases, which would be require to further validate our findings. Finally, the examination of splenomegaly was conducted by different physicians, which might contribute to subjective factors in determining splenomegaly, such as physician’s expertise and thoroughness, especially in cases with minor or subclinical splenomegaly.

Overall, we conclude that thrombocytopenia is not associated with splenomegaly in this set of malaria patients.

**Data availability**

F1000Research: Dataset 1. Data retrieved from the medical records of malaria patients in East Kalimantan, Indonesia, including age, gender, type of Plasmodium, thrombocyte count, and presence of splenomegaly, 

https://doi.org/10.5256/f1000research.16606.d22512

**Grant information**

The Islamic Development Bank funded this study.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**References**


Open Peer Review

Current Peer Review Status:  

Version 1

Reviewer Report 05 June 2019

https://doi.org/10.5256/f1000research.18149.r40937

© 2019 Hutagalung J. This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Jontari Hutagalung
Biomedical and Basic Health Technology, National Institute of Health Research and Development, Ministry of Health (Indonesia), Jakarta, Indonesia

This study is important and has a great impact for clinicians in the subject, however I found many lacks in the assessment methodologies, especially:

1. How to define the confirmed cases of this study (microscopic ELISA or PCR).

2. The methodologies to count the thrombocytopenia and splenomegaly.

3. It is important to separate the cases by species of Plasmodium and the day of infection.

Additional comments - there are some important things missing in this manuscript that need to be explained by the authors:

- The 1st paragraph; Please use the national Annual Parasite Incidence (API) below 1.00 per 1.000 population or the prevalence < 1%.

- The methodologies need to be addressed, because this is the most important; a) how did the authors use the definition of malaria cases in this study (giemsa 3%)? and b) for the methods of counting the parasite and thrombocytes (after treatment or before treatment, or before and after treatment), did the authors make QA for the test?

- Which prevalence of P. vivax is correct – 42.0% (from page 3 in the discussion) or 43.2% (from Table 1)?

- In the discussion I need more explanation about the aims of this study; “Discover the association between thrombocytopenia & splenomegaly”, please write about the following: a) the main function of thrombocytes and the kinds of situation risks decreased and for which patient conditions (acute or chronic diseases) and b) the authors should be addressing why their hypothesis was not considered significant.

Please find an annotated copy of the article here for my full comments.
Is the work clearly and accurately presented and does it cite the current literature?
Partly

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
No

If applicable, is the statistical analysis and its interpretation appropriate?
Partly

Are all the source data underlying the results available to ensure full reproducibility?
Partly

Are the conclusions drawn adequately supported by the results?
Partly

**Competing Interests:** No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

---

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com